Cellular Senescence Drives Brain Aging and Offers New Therapeutic Targets

Cellular senescence - when cells stop dividing but remain metabolically active - has emerged as a fundamental mechanism driving brain aging and neurodegeneration. This comprehensive analysis of 269 research papers spanning over two decades reveals how senescent cells accelerate diseases like Alzheimer's, Parkinson's, ALS, and Huntington's.

Researchers conducted a bibliometric analysis using advanced mapping tools to identify research trends and key findings. They examined publications from 2002 to 2025, tracking citation patterns, collaborative networks, and emerging therapeutic targets. The analysis revealed exponential growth in this field since 2018, with the US, China, and Italy leading research efforts.

Key discoveries include the central role of abnormal tau protein in triggering cellular senescence and the identification of senescent microglia as major contributors to chronic brain inflammation. These senescent immune cells release harmful inflammatory signals called SASP (senescence-associated secretory phenotype) that damage surrounding neurons and accelerate cognitive decline.

The most promising therapeutic approach involves senomorphics - drugs that modulate rather than eliminate senescent cells. Unlike senolytics that destroy senescent cells entirely, senomorphics target their harmful secretions while preserving potentially beneficial functions. This strategy could reduce neuroinflammation and slow disease progression with fewer side effects.

For longevity optimization, this research suggests that targeting cellular senescence could significantly extend healthspan by preserving cognitive function. However, the field remains fragmented, and more research is needed to develop specific biomarkers and targeted interventions. The findings offer hope for novel treatments that address the root causes of brain aging rather than just managing symptoms.